TG THERAPEUTICS INC (TGTX) Stock Price, Quote, News and Overview
NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD
TGTX Quote, Performance and Key Statistics
TG THERAPEUTICS INC
NASDAQ:TGTX (1/31/2025, 7:56:04 PM)
After market: 31.56 -0.14 (-0.44%)31.7
-1.66 (-4.98%)
The current stock price of TGTX is 31.7 USD. In the past month the price increased by 5.32%. In the past year, price increased by 92.59%.
TGTX Latest News, Press Releases and Analysis
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year...
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT...
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET...
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast...
TGTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.95B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About TGTX
Company Profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 319 full-time employees. The firm is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Company Info
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014 US
CEO: Michael S. Weiss
Employees: 300
Company Website: https://www.tgtherapeutics.com/
Investor Relations: https://ir.tgtherapeutics.com/
Phone: 18775758489
TGTX FAQ
What is the stock price of TGTX?
The current stock price of TGTX is 31.7 USD.
What is the symbol for TG THERAPEUTICS INC stock?
The exchange symbol of TG THERAPEUTICS INC is TGTX and it is listed on the Nasdaq exchange.
On which exchange is TGTX stock listed?
TGTX stock is listed on the Nasdaq exchange.
Is TGTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TGTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TGTX.
Does TGTX stock pay dividends?
TGTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of TGTX?
TGTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
What is the Short Interest ratio of TGTX stock?
The outstanding short interest for TGTX is 18.45% of its float.
TGTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX is one of the better performing stocks in the market, outperforming 93.24% of all stocks.
TGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TGTX. TGTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TGTX Financial Highlights
Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 60.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.45% | ||
| ROE | -7.48% | ||
| Debt/Equity | 1.27 |
TGTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to TGTX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 1366.25% and a revenue growth 42.85% for TGTX